70 results about "Self-replication" patented technology

Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and / or (b) promotes development or activity of antigen presenting cells, primarily dendritic cells. These vaccines employ one of several types of nucleic acid vectors, each with its own relative advantages: naked DNA plasmids, self-replicating RNA replicons and suicidal DNA-based on viral RNA replicons. Administration of such a vaccine results in enhance immune responses, primarily those mediated by CD8+ cytotoxic T lymphocytes, directed against the immunizing antigen part of the fusion polypeptide. Such vaccines are useful against tumor antigens, viral antigens and antigens of other pathogenic microorganisms and can be used in the prevention or treatment of diseases that include cancer and infections.

The present invention provides a gene expression system comprising: a) a self-replicating expression vector of flavivirus origin which includes the flavivirus 5′ untranslated region (UTR), at least a portion of the 5′ coding region for flavivirus core protein, the nucleotide sequence coding for the flavivirus non-structural proteins, and the complete or most of the 3′-terminal sequence of the flavivrus 3′UTR, required for self-replication of flavivirus genomic material, which vector is adapted to receive at least a nucleotide sequence without disrupting its replication capabilities; and b) at least a second vector that is capable of expressing flavivirus structural protein(s) and any other proteins required for packaging of the self-replicating expression vector into flavivirus viral particles which vector is engineered to prevent recombination with the self-replicating vector when in its presence.

A general method for producing EMS positive samples or samples containing nanostructures characteristic of self-replicating molecules like DNA by dilution and agitation. Methods of transduction into DNA information or for inducing EMS in an originating sample and transducing the EMS signal once induced into a naïve receiving sample. Diagnostic methods using this technology.

The invention relates to the field of biotechnology, and particularly relates to a shuttle plasmid vector, as well as a construction method and applications thereof. The shuttle plasmid vector can shuttle in yeast and Escherichia coli, and the nucleotide sequence of the shuttle plasmid vector is shown in SEQ ID NO.1. Compared with the prior art, he shuttle plasmid vector realizes the shuttling in yeast and bacteria, and has the capabilities of homologous recombination cloning, self replication and recombinant screening in yeast, as well as the characteristics of being stable in replication and maintenance and convenient for DNA purification and separation in bacteria.

The present invention includes a method and system for persistently self-replicating multiple ranges of cells through a copy-paste operation, in a multi dimensional spreadsheet. A set of ranges of cells is defined, wherein each range of cells has the same size. Each time the content of a range of cells belonging to this set is changed, a self-replication operation is performed automatically. The self-replication operation includes the steps of copying the changed range of cells onto a buffer; determining the set of ranges of cells to which the changed range of cells belongs to; identifying the ranges of cells belonging to the set; and pasting the content of the buffer in each of identified range of cells belonging to the set.

A method for inducing the differentiation of stem cells into tissue cells; a bioartificial organ, which contains the tissue cells; and a material for medical purposes, which contains the bioartificial organ are disclosed. Stem cells capable of proliferation, self-replication and differentiation are used and cultured by a hanging-drop method to three-dimensionally construct a cell mass of embryoid bodies, and the cell mass is cultured in the presence of HGF, GDNF, b-FGF, BMP7 and EGF. In this manner, the stem cells can be differentiated into tissue cells. A bioartificial organ can be produced using cells that have been differentiated into the tissue cells. Further, a material for medical purposes can be provided.

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

Disclosed are inducible cancer stem cells which are capable of in vitro self-replication and which are useful in research into cancer treatment and cancer-related drug development. Also disclosed are a production method for the above cells, cancer cells induced from the above stem cells, and a practical application of the cells. The disclosed inducible cancer stem cells which are capable of in vitro self-replication are characterised by satisfying requirements (1) and (2): (1) expressing six genes (POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene, and TERT gene) selected from among a specified gene group; (2) (a) having an abnormality which is either the modification of an endogenous cancer suppression gene, or (b) the up-regulation of an endogenous cancer related gene.

The invention discloses a broadband infrared ceramic material with an anti-aging function at normal temperature and a preparation method thereof. The preparation method is characterized by comprising the following steps of: crushing non-metallic minerals taking magnesium-rich silicate ore, spodumene and Guibao stone as main components, composite rare earth oxides taking praseodymium and neodymiumoxides as main components and reduced alloy iron powder; mixing the crushed powder with auxiliary materials for pulping; spraying and granulating; pressing; and sintering to obtain the broadband infrared ceramic material. The raw materials include the following components in percentage by weight: 8-60% of magnesium-rich silicate ore, 2-10% of spodumene, 5-15% of Guibao stone, 2-10% of reduced alloy iron powder and 2-8% of praseodymium and neodymium oxides; and the auxiliary materials include the following components in percentage by weight: 10-46% of ball clay and 1-8% of bonding agent. The broadband infrared ceramic material can continuously release infrared light beneficial to the human health at the normal temperature lower than 45 DEG C so as to generate a non-thermal biological resonance effect, thereby effectively improving the energy required by cell self-replication and an information transfer mechanism, enhancing activity functions such as organism metabolism and immunity andthe like, improving the disease resistance of human bodies, achieving the purposes of preventing and treating diseases and resisting ageing, and saving energy sources.

A flaviviral expression vector, construct and system are provided that each comprise a flaviviral replicon that faciliates intracellular self-replication leading to high-level expression of RNA and protein(s) encoded by a heterologous nucleic acid. The flaviviral expression vector, construct and system preferably use a Kunjin virus replicon and are of particular use as a vaccine delivery system that facilitates expression of immunogenic proteins and peptides that induce protective T cell immunity to viral infections and cancer. Vaccines may be administered in the form of DNA, RNA or virus like particles.

The present invention provides an induced cancer cell capable of self-replication in vitro which is useful in cancer therapy research and the research for cancer-related drug discovery, processes for production thereof, cancer cells induced by the malignant cells, and applications of these cells.The present invention provides an induced cancer stem cell capable of proliferation (self-replication) in vitro, wherein the induced cancer stem cell has the following two characteristics:(1) expressing the six genes (self-renewal related genes) POU5F1, NANOG, SOX2, ZFP42, LIN28, and TERT selected from a certain group of genes; and(2) having an aberration which is either (a) a mutation in an endogenous tumor suppressor gene or (b) increased expression of an endogenous cancer-related gene.

The invention relates to the biotechnical field, and concretely relates to an HSV1-H129-BAC and a mutant thereof. The above virus and the mutant thereof carry a bacterial artificial chromosome (BAC), can keep low-copy number self-replication in specific bacteria, and solve the disadvantages of unable long-term preservation, unable self-replication and inconvenient molecular biologic mutation reconstruction due to too large herpes virus genomes. The virus and the mutant thereof also carry a GFP reporter gene, and substantially develop the application prospect of the herpes virus as a tool virus. The invention also provides a construction method of the H129-BAC and the mutant thereof. The method allows H129 to be reconstructed in order to obtain H129-BAC and endows the H129-BAC with more mutant types; and the construction method, the H129 and the mutant thereof form a genetic modification platform with high application possibility.

The invention discloses an adenovirus / viruses A replicon chimeric vector hogcholeravaccine and application thereof. In the invention, a viruses A replicon vector expressing a hog cholera virus E2 protein is transmitted by the adenovirus having very strong gene transfer capability, an adenovirus / viruses A replicon chimeric vector vaccine efficiently expressing the CSFV.E2 protein is created, and microbe storage number of the vaccine is CGMCC.No.4146; The chimeric vector vaccine of the invention transmits the viruses A replicon chimeric vector vaccine expressing the CSFV.E2 protein through the adenovirus vector, so that efficient exogenous gene transfer capability of the adenovirus vector is utilized, and advantages of efficient exogenous gene expression of the viruses A replicon vector after self-replication and inducing strong cellular immune response are exerted, so that immunity of the vaccine is greatly enhanced, and immunizing dose is greatly reduced. The chimeric vector vaccine of the invention can induce high-level immune response on a pig body, and can completely protect the pig from attack of fatal hog cholera virulent virus.

Provided is a cell culture device having a culture area for culturing the stem or progenitor cells, from which tissues are formed. The cell culture device includes an oxygen adjusting part that adjusts the oxygen supply in the culture area, a controller that controls the oxygen adjusting part, and another controller that controls a first oxygen supply during a first period of the period, in which the stem cells and the progenitor cells differentiate; and a second oxygen supply greater in amount than the first supply during a second period, during which the stem cells and the progenitor cells differentiate, out of the whole culture period, and that controls the oxygen adjusting part based on the growth progress of the stem cells and the progenitor cells through self-replication to change the first oxygen supply to the second oxygen supply.

Convergent nanofabrication and nanoassembly methods are disclosed. Molecules and / or nanostructures are bound to supported binding tools and manipulated to bond together in desired locations and orientations to yield desired precise structures. Methods for precise fabrication of materials including diamond, graphene, nanotube, β-SiC (and precise modifications thereof, e.g. color centers for quantum computation and information processing and storage), halite structured materials including MgO, MgS, TiC, VN, ScN, precisely Mn doped ScN, NbN, HfC, TaC, HfxTayC, and metals, and graphenoid structures for photovoltaic devices are disclosed. Systems disclosed performing these methods can fabricate systems with similar capabilities, enabling allo- or self-replication, and have capabilities including: conversion and storage of energy; obtainment and processing of matter from abundant environmental sources including on other planets and fabrication of desired articles using same; converting wind power (esp. high altitude wind) to electricity with concurrent capture of CO2 and conversion thereof to useful feedstocks e.g. by reaction with CH4 from oceanic methane clathrates; growth of algae crops including food. Fabrication of arbitrarily long carbon nanotubes enable construction of orbital elevators.

A nucleotide sequence encoding the HIV regulatory protein NEF, REV or TAT or an immunologically active fragment thereof is inserted into a vector comprising papilloma virus nucleotide sequences necessary and sufficient for long-term persistence. The resulting vectors are self-replicating and have a high copy number. They express the HIV genes in high amounts for a long period of time. The vectors elicit both a humoral and cell-mediated immune response and are therefore potential DNA immunization vaccines against HIV. The invention is directed to said vectors and vaccines and to a method for preparing the vectors. The invention is further directed to a host cell comprising the vector, to the use of the vector in the manufacture of a vaccine and to a method of preventing or treating HIV.

The present invention relates to a method and substance for maintaining the pluripotency and self-replication ability of a stem cell, such as a hematopoietic stem cell, while keeping it undifferentiated. Specifically, the present invention provides a composition for maintaining the expansion or pluripotency of a stem cell, comprising active STAT5, and a method using the same. STAT5 may be in the form of a protein or a nucleic acid. The composition may contain a cellular physiologically active substance (e.g., SCF, TPO, Flt-3L, etc.). The present invention also relates to a cell, a tissue and an organ prepared from the stem cell.

The invention relates to the technical field of medicine chemistry and in particular to a pyrimidinoindole compound as well as a preparation method and application thereof. The invention mainly relates to synthesis of a pyrimidinoindole-containing compound and application thereof in the field of medicines. Specifically, the invention relates to the pyrimidinoindole compound which is capable of stimulating self replication of stem cells in vitro without differentiation, and thus the pyrimidinoindole compound has application prospects in expanding application of stem cells in various treatment fields.

The invention relates to a preparation method of radioresistant bacterium that contains the activity of luciferase. The invention takes plasmids originating from radioresistant bacterium deinococcus radiopugnans as a base to recompose with plasmids that can ensure self-duplication in escherichia coli to form a shuttle carrier. The carrier is recomposed with DNA fragments in the luciferase gene lux field that originates from into host DNA of photinus pyralis from North America into plasmids with luciferase genes. Then the plasmids are introduced into bacterial of a radioresistant bacterium family, deinococcus grandis are transformed by the constructed plasmids to get chloramphenicol resistant strains. The radioresistant bacterium prepared by the method of the invention can be used in various fields of outdoor opening and close environments. The carrier has the luciferase genes, thereby having better application value to real-time supervision and control on the propagation, distribution and influence to the environment of the recomposed transformants.

A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5′-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G->A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C / R mutations, possess greater efficiency of transduction and / or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.

The invention discloses a preparation method of a cortex albiziae neolignan monomeric compound and belongs to the technical field of biochemistry. The prepared compound can effectively treat FFAs-induced lipid metabolism disorder and fatty degeneration and can reduce the lipid droplet area by about 3 times at the administration concentration of 20 [mu] M 24 h after administration; the compound cansignificantly enhance cell viability of HUVEC and significantly promote self replication of cells so as to promote proliferation of endothelial cell HUVEC. The cell viability can reach 242.233% in control at the administration concentration of 40 [mu] M 24 h after administration. The prepared compound can remarkably inhibit HG-induced reactive oxygen species (ROS) of the HUVEC cells and reduce the average flurescence intensity of an HG group to 176.36% from 818.37%.

A novel recombinant chimera of DNA construct having esat-6 region of Mycobacterium tuberculosis and kinesin region of Leishmania donovani cloned together on two sides of self cleaving peptide in a DNA vaccine vector pVAX-1 wherein the chimeric construct is operatively linked to a transcriptional promoter thus capable of self replication and expression within the mammalian cell, and the process of preparation thereof comprising: analysis of the predicted protein sequence of kinesin motor domain and esat-6 domain using Promiscuous MHC Class-1 Binding Peptide Prediction Servers; amplification of gene coding for kinesin motor domain and esat-6 domain; cloning of kinesin esat-6 gene region in pGEM-T™ vector for sequence analysis; generation of chimeric construct by directional cloning in pVAX-1 vector. In-vitro expression analysis of kinesin motor domain and esat-6 domain from the clones using cell free translation system and immunogenicity studies; and splenocyte proliferation and cytokines studies using the above mentioned constructs.

The invention discloses a kind of liver cancer target tropism to dissolve the lump adenovirus, its preparation method and use. The invention adenovirus is starts sub- AF0.3 using oxygen deficit reply part HRE and the AFP core to construct mixed and the start, constructs the retention to have the E1 duplication start area gene the reorganization adenovirus shuttle material particle, again constructs the reorganization adenovirus material particle after the homologous reorganization, the extension dyes the cell, the packing leaves the goal reorganization virus pellet. The invention adenovirus has the liver cancer target tropism, can oneself duplicate in the liver cancer cell, achieves the decomposition cancer cell the goal. Has highly effective, not sends the sudden change function, the safe highly effective merit, may use in to prepare the cancer cell the treatment medicine.

The invention relates to construction of a free non-methanol induced pichia pastoris expression vector and an application of the expression vector in enzyme recombination expression, and belongs to the technical field of genetic engineering. The non-methanol induced pichia pastoris expression vector is obtained by inserting a kluyveromyces lactis autonomous replication sequence PARS2 and a pichiapastoris promoter PGCW14 sequence into a vector framework, and constructing a free vector with a self-replication sequence. Compared with the general integrated recombinant pichia pastoris engineeringbacteria, the free recombinant pichia pastoris engineering bacteria constructed by the vector have obviously-improved capability of secreting and producing recombinant enzymes. In addition, the fermentation raw materials have wide sources, and the production cost is low.

The invention discloses an adenovirus / viruses A replicon chimeric vector hogcholeravaccine and application thereof. In the invention, a viruses A replicon vector expressing a hog cholera virus E2 protein is transmitted by the adenovirus having very strong gene transfer capability, an adenovirus / viruses A replicon chimeric vector vaccine efficiently expressing the CSFV.E2 protein is created, and microbe storage number of the vaccine is CGMCC.No.4146; The chimeric vector vaccine of the invention transmits the viruses A replicon chimeric vector vaccine expressing the CSFV.E2 protein through the adenovirus vector, so that efficient exogenous gene transfer capability of the adenovirus vector is utilized, and advantages of efficient exogenous gene expression of the viruses A replicon vector after self-replication and inducing strong cellular immune response are exerted, so that immunity of the vaccine is greatly enhanced, and immunizing dose is greatly reduced. The chimeric vector vaccine of the invention can induce high-level immune response on a pig body, and can completely protect the pig from attack of fatal hog cholera virulent virus.

The present invention relates to methods exogenous nucleic acid molecules, such as RNA, that encode an antibody or antigen-binding fragment of an antibody, and optionally encode a cellular modulation factor and / or a potentiation factor. The cellular modulation factor is a factor that results in increased expression of the antibody and / or antigen-binding fragment. The potentiation factor is a factor that provides desired antibody effector or other properties. The exogenous nucleic acid molecules can be DNA or RNA, as mRNA (including self-replication RNA and non-self-replicating RNA). The invention also relates method for administering the exogenous nucleic acid molecules to a subject to achieve production of the encoded antibody or antigen-binding fragment in the subject to provide, for example, prophylactic or therapeutic passive immunity.